65,437 trials
Chronic Pain · Back Pain
Primary: Recruitment Rate — 32 Participants
Colorectal Cancer
Primary: Concordance Between Patient Preference and Test Ordered — 148; 147 Participants — p=0.40
Esophageal Cancer
Primary: Progression-free Survival Rate — 7 weeks
Growth Hormone · Amino Acid
Primary: Change From Baseline of Growth Hormone — 1.15; -0.48 nanograms/ml — p=0.01
Myopia
Primary: Subjective Comfort — 10; 9; 10; 9 units on a scale
Myopia
Primary: Comfort — 8.85; 9.06; 8.71; 8.84 units on a scale
Myopia
Primary: Lens Fit - Centration — 88; 97; 99; 100 percentage of eyes
Solid Tumor · Multiple Myeloma
Primary: Percentage of Participants Who Experienced One or More Dose-limiting Toxicities (DLTs) — 0; 0; 13; 0 Percentage of Participants
Duchenne Muscular Dystrophy (DMD) · Cardiomyopathy
Primary: Cardiac Ejection Fraction as Measured by Echocardiogram — 54.6; 55.2 percentage of blood leaving the heart
Multiple Sclerosis
Primary: Change From Screening in Selective Reminding Test - Long-Term Storage (SRT-LTS) Raw Score — 6.32; 4.46 raw score — p=0.4940
Obesity · Overweight
Primary: Weight at End of Behavioural Weight Loss Program, 12 Weeks — 89.02; 90.09 kilograms — p=>.05
Healthy
Primary: Maximum Drug Concentration (Cmax) in Plasma Determined Directly From Individual Concentration-time Data — 20.0; 17.9; 18.4; 17.5 ng/mL
Erythema · Edema
Primary: Number of Subjects With Observed Local Erythema Based on 5 Point Scale — 0 Participants
Gastrointestinal Lesions
Primary: Endoscopic Score - Cryer Score — 4; 4 Cryer score
Asthma
Primary: Change From Baseline in Trough FEV1 (L) in Non-atopic Patients at Week 12 - Full Analysis Set — 0.05; 0.03 liter — p=0.7269